Search

Your search keyword '"Hara, Kohei"' showing total 524 results
Start Over Author "Hara, Kohei"
524 results on '"Hara, Kohei"'

1. A Job Interview Dialogue System with Autonomous Android ERICA

Author

Inoue, Koji, Hara, Kohei, Lala, Divesh, Nakamura, Shizuka, Takanashi, Katsuya, Kawahara, Tatsuya, Angrisani, Leopoldo, Series Editor, Arteaga, Marco, Series Editor, Panigrahi, Bijaya Ketan, Series Editor, Chakraborty, Samarjit, Series Editor, Chen, Jiming, Series Editor, Chen, Shanben, Series Editor, Chen, Tan Kay, Series Editor, Dillmann, Rüdiger, Series Editor, Duan, Haibin, Series Editor, Ferrari, Gianluigi, Series Editor, Ferre, Manuel, Series Editor, Hirche, Sandra, Series Editor, Jabbari, Faryar, Series Editor, Jia, Limin, Series Editor, Kacprzyk, Janusz, Series Editor, Khamis, Alaa, Series Editor, Kroeger, Torsten, Series Editor, Liang, Qilian, Series Editor, Martín, Ferran, Series Editor, Ming, Tan Cher, Series Editor, Minker, Wolfgang, Series Editor, Misra, Pradeep, Series Editor, Möller, Sebastian, Series Editor, Mukhopadhyay, Subhas, Series Editor, Ning, Cun-Zheng, Series Editor, Nishida, Toyoaki, Series Editor, Pascucci, Federica, Series Editor, Qin, Yong, Series Editor, Seng, Gan Woon, Series Editor, Speidel, Joachim, Series Editor, Veiga, Germano, Series Editor, Wu, Haitao, Series Editor, Zhang, Junjie James, Series Editor, Marchi, Erik, editor, Siniscalchi, Sabato Marco, editor, Cumani, Sandro, editor, Salerno, Valerio Mario, editor, and Li, Haizhou, editor

Published
2021
Full Text
View/download PDF

6. Study of nasopharyngeal bacterial flora. Variations in nasopharyngeal bacterial flora in schoolchildren and adults when administered antimicrobial agents

Author

Konno, Masatoshi, Baba, Shunkichi, Mikawa, Haruki, Hara, Kohei, Matsumoto, Fumio, Kaga, Kimitaka, Nishimura, Tadao, Kobayashi, Toshimitsu, Furuya, Nobuhiko, Moriyama, Hiroshi, Okamoto, Yoshitaka, Furukawa, Mituru, Yamanaka, Noboru, Matsushima, Toshiharu, Yoshizawa, Yasuyuki, Kohno, Shigeru, Kobayashi, Kunihiko, Morikawa, Akihiro, Koizumi, Shoichi, Sunakawa, Keisuke, Inoue, Matsuhisa, and Ubukata, Kimiko

Published
2007
Full Text
View/download PDF

8. Study of nasopharyngeal bacterial flora. Second report. Variations in nasopharyngeal bacterial flora in children aged 6 years or younger when administered antimicrobial agents. Part 2

Author

Konno, Masatoshi, Baba, Shunkichi, Mikawa, Haruki, Hara, Kohei, Matsumoto, Fumio, Kaga, Kimitaka, Nishimura, Tadao, Kobayashi, Toshimitsu, Furuya, Nobuhiko, Moriyama, Hiroshi, Okamoto, Yoshitaka, Furukawa, Mituru, Yamanaka, Noboru, Matsushima, Toshiharu, Yoshizawa, Yasuyuki, Kohno, Shigeru, Kobayashi, Kunihiko, Morikawa, Akihiro, Koizumi, Shoichi, Sunakawa, Keisuke, Inoue, Matsuhisa, and Ubukata, Kimiko

Published
2006
Full Text
View/download PDF

9. Study of nasopharyngeal bacterial flora. Second report. Variations in nasopharyngeal bacterial flora in children aged 6 years or younger when administered antimicrobial agents. Part 1

Author

Konno, Masatoshi, Baba, Shunkichi, Mikawa, Haruki, Hara, Kohei, Matsumoto, Fumio, Kaga, Kimitaka, Nishimura, Tadao, Kobayashi, Toshimitsu, Furuya, Nobuhiko, Moriyama, Hiroshi, Okamoto, Yoshitaka, Furukawa, Mituru, Yamanaka, Noboru, Matsushima, Toshiharu, Yoshizawa, Yasuyuki, Kohno, Shigeru, Kobayashi, Kunihiko, Morikawa, Akihiro, Koizumi, Shoichi, Sunakawa, Keisuke, Inoue, Matsuhisa, and Ubukata, Kimiko

Published
2006
Full Text
View/download PDF

10. Study of upper respiratory tract bacterial flora: first report. Variations in upper respiratory tract bacterial flora in patients with acute upper respiratory tract infection and healthy subjects and variations by subject age

Author

Konno, Masatoshi, Baba, Shunkichi, Mikawa, Haruki, Hara, Kohei, Matsumoto, Fumio, Kaga, Kimitaka, Nishimura, Tadao, Kobayashi, Toshimitsu, Furuya, Nobuhiko, Moriyama, Hiroshi, Okamoto, Yoshitaka, Furukawa, Mituru, Yamanaka, Noboru, Matsushima, Toshiharu, Yoshizawa, Yasuyuki, Kohno, Shigeru, Kobayashi, Kunihiko, Morikawa, Akihiro, Koizumi, Shoichi, Sunakawa, Keisuke, Inoue, Matsuhisa, and Ubukata, Kimiko

Published
2006
Full Text
View/download PDF

13. Fabrication of TiO 2 -graphene photocatalyst by direct chemical vapor deposition and its anti-fouling property

Author

Misaki Ota, Norikazu Nishiyama, Yuichiro Hirota, Hara Kohei, Daisuke Ino, Yoshiaki Uchida, and Meika Aidil Fitri

Subjects
Materials science, Graphene, Inorganic chemistry, chemistry.chemical_element, 02 engineering and technology, Chemical vapor deposition, 010402 general chemistry, 021001 nanoscience & nanotechnology, Condensed Matter Physics, 01 natural sciences, 0104 chemical sciences, law.invention, chemistry.chemical_compound, symbols.namesake, chemistry, law, Titanium dioxide, Photocatalysis, symbols, Deposition (phase transition), General Materials Science, 0210 nano-technology, Raman spectroscopy, Carbon, Layer (electronics)
Abstract

In this report, we demonstrated a successful fabrication of titanium dioxide (TiO2)-graphene composite for photocatalytic applications by direct deposition of graphene onto TiO2 nanoparticles (P25) via a chemical vapor deposition (CVD) method using methanol or propylene as the carbon sources. The successful formation of the graphene layer was confirmed from its Raman spectrum showing typical bands for graphitic structure. Furthermore, HR-TEM images of the composites showed a less than 1 nm-thick graphene layer surrounding the TiO2 particles. The TiO2-graphene composites exhibited approximately 2-fold higher photocatalytic activity than the bare TiO2 for photocatalytic degradation of methylene blue and estradiol as model pollutants. We also investigated the anti-fouling effect of the TiO2-graphene composite and the bare TiO2 previously immersed in synthetic groundwater (SGW). The kinetic constants of photo-degradation on TiO2-graphene composites immersed in SGW containing a foulant exhibit enhancement of an anti-fouling effect compared to the bare TiO2. The graphene was thought to protect the TiO2 from the foulant.

Published
2017

28. Decomposition of Pesticides in Water through the Use of a Slurry-Type TiO2 Water Treatment Apparatus

Author

Daisuke Ino, Masato Aizawa, Balakrishnan Sarangaraja, Yuko Maruo, Hara Kohei, and Yasuhiro Hashimoto

Subjects
021110 strategic, defence & security studies, Environmental Engineering, Waste management, Chemistry, Health, Toxicology and Mutagenesis, Ecological Modeling, 0211 other engineering and technologies, 02 engineering and technology, 010501 environmental sciences, Pesticide, 01 natural sciences, Pollution, Decomposition, Slurry, Water treatment, Waste Management and Disposal, 0105 earth and related environmental sciences, Water Science and Technology
Published
2016

35. Noninvasive assessment of right heart function by 81mKr equilibrium radionuclide ventriculography in chronic pulmonary diseases

Author

Takao, Masami, Miyahara, Yoshiyuki, Shinboku, Hiroki, Nishijima, Kyoji, Morimitsu, Takuya, and Hara, Kohei

Subjects
Lung diseases -- Diagnosis, Radioisotope scanning, Health, Diagnosis
Abstract

Noninvasive multigated equilibrium radionuclide ventriculography with krypton-81m ([.sup.81mKr]) was used to assess right heart relaxation in patients with chronic pulmonary diseases (CPD). The subjects consisted of 30 patients with CPD [...]

Published
1996

39. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis

Author

Oda, Hiroshige, Kadota, Jun-ichi, Kohno, Shigeru, and Hara, Kohei

Subjects
Chemotaxis -- Physiological aspects, Neutrophils -- Physiological aspects, Diffuse panbronchiolitis -- Drug therapy, Erythromycin -- Physiological aspects, Health, Drug therapy, Physiological aspects
Abstract

The efficacy of low dose long-term erythromycin (EM) therapy in the treatment of chronic lower respiratory tract disease, including diffuse panbronchiolitis (DPB), has been reported, but its therapeutic mechanism is [...]

Published
1994

40. Two-color analysis of lymphocyte subsets of bronchoalveolar lavage fluid and peripheral blood in Japanese patients with sarcoidosis

Author

Mukae, Hiroshi, Kohno, Shigeru, Morikawa, Toru, Kusano, Shiro, Kadota, Jun-ichi, and Hara, Kohei

Subjects
T cells -- Physiological aspects, Cell differentiation -- Physiological aspects, Sarcoidosis -- Physiological aspects, Disease susceptibility -- Evaluation -- Physiological aspects, Health, Evaluation, Physiological aspects
Abstract

Analysis of T-cell surface markers was carried out in peripheral blood and bronchoalveolar lavage (BAL) fluid of Japanese patients with sarcoidosis to examine the influence of differing racial background. The [...]

Published
1994

41. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis

Author

Kohno, Shigeru, Koga, Hironobu, Kaku, Mitsuo, Maesaki, Shigefumi, and Hara, Kohei

Subjects
Ethambutol -- Health aspects -- Evaluation, Antitubercular agents -- Evaluation -- Health aspects, Tuberculosis -- Drug therapy -- Health aspects, Ofloxacin -- Health aspects -- Evaluation, Health, Drug therapy, Evaluation, Health aspects
Abstract

The efficacy of ofloxacin, rifampicin and isoniazid was prospectively compared with the regimen of ethambutol, rifampicin and isoniazid for the primary treatment of pulmonary tuberculosis in 124 patients. All drugs were given orally daily for nine months. Culture conversion rates three months after starting treatment were 98 percent in the ofloxacin group and 94 percent in the ethambutol group; by six months all patients in both groups were culture-negative. Significant radiological improvement of pulmonary infiltrates was observed in 83 percent of the ofloxacin group and 85 percent of the ethambutol group one year after starting treatment. No relapse in either group was observed during a two-year follow-up period after the cessation of chemotherapy. Ofloxacin appears to be as useful as ethambutol in the treatment of pulmonary tuberculosis when either drug is combined with isoniazid and rifampicin. (Chest 1992; 102:1815-18) MIC = minimum inhibitory concentration, Ofloxacin is a new quinolone antimicrobial with a broad spectrum of activity for Gram-positive and Gram-negative bacteria, Legionella species,[1] Mycoplasma pneumoniae,[2] Chlamydia psittaci and Mycobacterium tuberculosis.[3-6] The excellent antimycobacterial activity [...]

Published
1992

50. Comparison of Four Carbapenems; Imipenem-Cilastatin, Panipenem-Betamipron, Meropenem, and Biapenem with Review of Clinical Trials in Japan

Author

Kohno, Shigeru, Tomono, Kazunori, Maesaki, Shigefumi, Hirakata, Yoichi, and Hara, Kohei

Subjects
polycyclic compounds, biochemical phenomena, metabolism, and nutrition, bacterial infections and mycoses
Abstract

The development of carbapenem gives a revolutionary impact to the chemotherapy of infectious diseases. The bacteriological and clinical efficacies of carbapenems, including imipenem/cilastatin, panipenem/betamipron, meropenem and biapenem, were evaluated. All four carbapenems were potent against gram-positive and gram-negative bacteria except Stenotrophomonas maltophilia. The antimicrobial activities of meropenem against Enterobacteriaceae were slightly superior to other carbapenems. Imipenem and panipenem were slightly more active against gram-positive bacteria than meropenem and biapenem. Biapenem was the most potent against Acinetobacter anitratus. The in vitro activity of imipenem was compared between 1990 and 1992 in Nagasaki University Hospital. The resistance rate of S. aureus, whose MIC is higher than 25 mg/l, increased from 3% to 22%, S. pneumoniae, whose MIC is higher than 0.05 mg/l, increased from 9% to 30% and P. aeruginosa, whose MIC is higher than 5 mg/l, increased from 20% to 32%. The isolation rates of S. maltophilia from sputum increased gradually from 0.9% in 1984 to 3.5% in 1991. The clinical efficacy rates of imipenem/cilastatin and panipenem/betamipron were 79% and 77%, and the rates of meropenem and biapenem 100% and 96.2% for the treatment of respiratory infection in our department, respectively. The efficacy rates of imipenem/cilastatin decreased from 79% to 67.7% after being commercialized. This decline was due to administration to patients with severe underlying diseases and with infection caused by resistant strains such as P. aeruginosa and S. aureus. The phase II and III trials of carbapenems in internal medicine, which were performed separately in Japan, showed that the clinical efficacy rates were 73%, 79%, 86% and 89%, and the rates of adverse reaction were 4.7%, 3.3%, 1.8% and 2.2% in imipenem /cilastatin, panipenem, betamipron, meropenem and biapenem, respectively. Newly developed, Acta medica Nagasakiensia. 1998, 43(3-4), p.12-18

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results